Paper Details

  1. Home
  2. Paper Details

Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.

Author: BuckSteven A, CaldwellJ Timothy, EdwardsHolly, GeYubin, QingWilliam Y, TaubJeffrey W, WangGuan, WangZhihong

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Panobinostat, a novel pan-HDAC inhibitor, showed significant antitumor activity against high-risk neuroblastoma cell lines. The combination of panobinostat with cisplatin, doxorubicin, or etoposide resulted in highly synergistic antitumor interactions, accompanied by cooperative induction of apoptosis. Panobinostat treatment down-regulated the CHK1 pathway and abrogated the G2 cell cycle checkpoint, indicating that suppression of the CHK1 pathway by panobinostat is responsible for the synergistic antitumor interactions. This study provides a rationale for clinical evaluation of panobinostat combined with cisplatin, doxorubicin, or etoposide for treating children with high-risk neuroblastoma.
Paper Details　
Original Abstract of the Article :
High-risk neuroblastoma remains a therapeutic challenge with a long-term survival rate of less than 40%. Therefore, new agents are urgently needed to overcome chemotherapy resistance so as to improve the treatment outcome of this deadly disease. Histone deacetylase (HDAC) inhibitors (HDACIs) represe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786928/

データ提供：米国国立医学図書館（NLM）

Combating Neuroblastoma: A Battle Against a Deadly Desert Storm

Neuroblastoma, a particularly aggressive type of childhood cancer, is like a deadly desert storm, relentlessly attacking the body. This research investigates the potential of combining a pan-histone deacetylase inhibitor (HDACI), panobinostat, with conventional chemotherapy drugs to enhance treatment efficacy in high-risk neuroblastoma. The authors demonstrate that combining panobinostat with cisplatin, doxorubicin, or etoposide results in synergistic antitumor interactions, offering a potential strategy to overcome chemotherapy resistance. This research is like a quest for a cure in the desert of neuroblastoma, seeking a way to defeat this formidable foe.

A New Strategy for Treatment: Synergistic Action Against Neuroblastoma

This research highlights the potential of combining panobinostat with conventional chemotherapy drugs to enhance treatment efficacy in high-risk neuroblastoma. The study demonstrates that this combination therapy results in synergistic antitumor interactions, effectively combating chemotherapy resistance. This discovery offers a promising new approach to treating neuroblastoma, potentially improving treatment outcomes and survival rates. It's like finding a hidden oasis in the desert of neuroblastoma, providing a source of relief and potentially saving lives.

Hope for the Future: New Weapons in the Fight Against Neuroblastoma

This research provides a glimmer of hope for children battling neuroblastoma. The discovery of a synergistic treatment combination offers a potential breakthrough in the fight against this deadly disease. This research encourages continued innovation and exploration of new therapies, seeking to improve treatment outcomes and ultimately eradicate this devastating cancer. It's like a caravan of researchers and clinicians working together, guided by hope and driven by a desire to protect the most vulnerable members of our society.

Dr. Camel's Conclusion

This research is a testament to the perseverance and ingenuity of the scientific community in the face of a formidable foe. The discovery of a synergistic treatment combination for high-risk neuroblastoma offers a beacon of hope in the desert of childhood cancer. This research encourages us to remain steadfast in our commitment to finding cures for these devastating diseases and protecting our children from the ravages of cancer.

Date :
  1. Date Completed 2014-06-16
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24098799

DOI: Digital Object Identifier

PMC3786928

Related Literature

Article Analysis
・Effects of panobinostat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.